You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

LODINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lodine, and when can generic versions of Lodine launch?

Lodine is a drug marketed by Wyeth Pharms Inc and is included in two NDAs.

The generic ingredient in LODINE is etodolac. There are twenty-three drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the etodolac profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lodine

A generic version of LODINE was approved as etodolac by ABRAXEOLUS on April 11th, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LODINE?
  • What are the global sales for LODINE?
  • What is Average Wholesale Price for LODINE?
Summary for LODINE
US Patents:0
Applicants:1
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 118
Patent Applications: 4,501
DailyMed Link:LODINE at DailyMed
Drug patent expirations by year for LODINE

US Patents and Regulatory Information for LODINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Pharms Inc LODINE etodolac CAPSULE;ORAL 018922-002 Jan 31, 1991 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE XL etodolac TABLET, EXTENDED RELEASE;ORAL 020584-002 Oct 25, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE etodolac TABLET;ORAL 018922-005 Jun 28, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE etodolac CAPSULE;ORAL 018922-003 Jan 31, 1991 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LODINE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc LODINE etodolac CAPSULE;ORAL 018922-002 Jan 31, 1991 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE etodolac CAPSULE;ORAL 018922-003 Jan 31, 1991 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE etodolac TABLET;ORAL 018922-004 Jul 29, 1993 ⤷  Sign Up ⤷  Sign Up
Wyeth Pharms Inc LODINE etodolac CAPSULE;ORAL 018922-003 Jan 31, 1991 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for LODINE

See the table below for patents covering LODINE around the world.

Country Patent Number Title Estimated Expiration
Denmark 155328 ⤷  Sign Up
Sweden 387122 FORFARANDE FOR FRAMSTELLNING AV PYRANO(3,4-B)INDOL- ELLER TIOPYRANO(3,4-B)INDOLDERIVAT MED TERAPEUTISK VERKAN ⤷  Sign Up
Philippines 11673 A PROCESS FOR THE PREPARATION OF PYRANO(THIOPYRANO)(3,4-B)INDOLE DERIVATIVES ⤷  Sign Up
Philippines 10625 1,3,4,9-TETRAHYDROPYRANO-OR 1,3,4,9-TETRAHYDROTHIOPYRANO-(3,4-B)INDOLE DERIVATIVES ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.